Table 2.
Patient Exposure to Combinations of VA Preparations and mAb.a
| Number of Patients Exposed (Total Exposures) | Helixor A | Helixor M | Helixor P | mAb Therapy (No VA) | Total |
|---|---|---|---|---|---|
| Ado-trastuzumab emtansine | 2 (17) | — | — | — | 2 (17) |
| Bevacizumab | 19 (87) | 10 (94) | 2 (7) | 3 (18) | 32 (206) |
| Cetuximab | 8 (104) | 5 (31) | 1 (11) | 1 (4) | 13 (150) |
| Ofatumumab | — | — | — | 1 (3) | 1 (3) |
| Panitumumab | 1 (3) | 1 (9) | — | 1 (1) | 3 (13) |
| Rituximab | — | 1 (1) | 1 (3) | 1 (6) | 3 (10) |
| Trastuzumab | 8 (94) | 1 (13) | — | 3 (36) | 11 (143) |
| VA therapy (no mAb) | 6 (32) | 6 (55) | 3 (42) | — | 12 (129) |
| Total | 38 (337) | 20 (203) | 6 (63) | 8 (68) | 56 (671) |
Abbreviations: VA, Viscum album L; mAb, monoclonal antibodies.
a
Values represent the number of patients exposed, with the total number of exposures in parentheses.